A detailed history of Virtus ETF Advisers LLC transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 38,386 shares of TBPH stock, worth $378,485. This represents 0.15% of its overall portfolio holdings.

Number of Shares
38,386
Previous 38,386 -0.0%
Holding current value
$378,485
Previous $325,000 4.92%
% of portfolio
0.15%
Previous 0.17%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$8.29 - $9.92 $31,327 - $37,487
3,779 Added 10.92%
38,386 $325,000
Q1 2024

May 15, 2024

BUY
$8.22 - $11.59 $40,927 - $57,706
4,979 Added 16.81%
34,607 $310,000
Q4 2023

Feb 15, 2024

BUY
$8.58 - $11.4 $3,397 - $4,514
396 Added 1.35%
29,628 $333,000
Q3 2023

Nov 07, 2023

SELL
$8.38 - $10.44 $31,651 - $39,431
-3,777 Reduced 11.44%
29,232 $252,000
Q2 2023

Aug 14, 2023

BUY
$10.16 - $11.92 $56,255 - $66,001
5,537 Added 20.16%
33,009 $341,000
Q1 2023

May 15, 2023

BUY
$9.87 - $11.44 $4,767 - $5,525
483 Added 1.79%
27,472 $298,000
Q4 2022

Feb 14, 2023

SELL
$9.65 - $11.34 $5,018 - $5,896
-520 Reduced 1.89%
26,989 $302,000
Q3 2022

Nov 14, 2022

BUY
$8.39 - $10.22 $3,356 - $4,088
400 Added 1.48%
27,509 $279,000
Q2 2022

Aug 12, 2022

SELL
$8.41 - $10.34 $77,792 - $95,645
-9,250 Reduced 25.44%
27,109 $246,000
Q4 2021

Feb 14, 2022

BUY
$7.42 - $11.05 $88,720 - $132,124
11,957 Added 49.0%
36,359 $402,000
Q3 2021

Nov 15, 2021

SELL
$6.77 - $14.41 $15,171 - $32,292
-2,241 Reduced 8.41%
24,402 $181,000
Q2 2021

Aug 10, 2021

SELL
$14.52 - $22.46 $90,430 - $139,880
-6,228 Reduced 18.95%
26,643 $387,000
Q1 2021

May 17, 2021

BUY
$16.57 - $21.08 $14,995 - $19,077
905 Added 2.83%
32,871 $671,000
Q4 2020

Feb 12, 2021

BUY
$14.89 - $20.16 $131,300 - $177,770
8,818 Added 38.09%
31,966 $568,000
Q3 2020

Nov 13, 2020

BUY
$14.79 - $22.49 $28,840 - $43,855
1,950 Added 9.2%
23,148 $342,000
Q2 2020

Aug 05, 2020

SELL
$20.64 - $30.69 $118,576 - $176,314
-5,745 Reduced 21.32%
21,198 $445,000
Q1 2020

May 14, 2020

SELL
$17.84 - $31.21 $40,550 - $70,940
-2,273 Reduced 7.78%
26,943 $623,000
Q4 2019

Feb 13, 2020

SELL
$16.12 - $25.89 $229,323 - $368,311
-14,226 Reduced 32.75%
29,216 $756,000
Q3 2019

Nov 12, 2019

SELL
$16.51 - $23.78 $120,671 - $173,808
-7,309 Reduced 14.4%
43,442 $846,000
Q2 2019

Aug 13, 2019

BUY
$15.6 - $25.15 $345,368 - $556,795
22,139 Added 77.38%
50,751 $829,000
Q1 2019

May 14, 2019

BUY
$22.57 - $28.15 $139,234 - $173,657
6,169 Added 27.49%
28,612 $649,000
Q4 2018

Feb 05, 2019

SELL
$22.52 - $35.07 $220,313 - $343,089
-9,783 Reduced 30.36%
22,443 $574,000
Q3 2018

Nov 14, 2018

BUY
$22.83 - $32.67 $49,563 - $70,926
2,171 Added 7.22%
32,226 $1.05 Million
Q2 2018

Aug 10, 2018

SELL
$22.06 - $25.52 $64,724 - $74,875
-2,934 Reduced 8.89%
30,055 $682,000
Q1 2018

May 14, 2018

SELL
$23.37 - $29.71 $45,337 - $57,637
-1,940 Reduced 5.55%
32,989 $800,000
Q4 2017

Feb 14, 2018

BUY
$25.82 - $35.66 $188,047 - $259,711
7,283 Added 26.34%
34,929 $974,000
Q2 2017

Aug 14, 2017

BUY
N/A
27,646
27,646 $1.1 Million

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $658M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.